Rapport Therapeutics (RAPP) Amortizatization of Intangibles (2023 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Amortizatization of Intangibles of $364000.0 for Q1 2026, down 16.51% year-over-year from $436000.0 in Q1 2025, and down 66.04% quarter-over-quarter from $1.1 million in Q4 2025.
Powered by 
Analysis
Rapport Therapeutics (RAPP) Amortizatization of Intangibles (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Amortizatization of Intangibles for 3 consecutive years, with $364000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 16.51% year-over-year to $364000.0; the TTM figure through Mar 2026 stood at $1.3 million (down 50.39% YoY), while the FY2025 annual figure was $1.4 million, down 56.52% from the prior year.
- Amortizatization of Intangibles declined to $364000.0 in Q1 2026 per RAPP's latest filing, from $1.1 million in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $2.0 million in Q3 2024 and bottomed at -$560000.0 in Q4 2024.
- Historically, Amortizatization of Intangibles has averaged $552333.3 across 3 years, with a median of $436000.0 in 2025.
- On a YoY basis, Amortizatization of Intangibles climbed as much as 291.43% in 2025 and fell as far as 110.39% in 2025.
- Rapport Therapeutics' Amortizatization of Intangibles stood at -$560000.0 in 2024, then surged by 291.43% to $1.1 million in 2025, then plunged by 66.04% to $364000.0 in 2026.
- Business Quant data shows RAPP's Amortizatization of Intangibles at $364000.0 in Q1 2026, $1.1 million in Q4 2025, and -$204000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Rapport Therapeutics | 2.17 Bn | 2.17 Bn | - | 595,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 595,000.00 |
| Mar 31, 2026 | 582,000.00 |
| Dec 31, 2025 | 571,000.00 |
| Sep 30, 2025 | 567,000.00 |
| Jun 30, 2025 | 458,000.00 |
| Mar 31, 2025 | 436,000.00 |
| Dec 31, 2024 | -560,000.00 |
| Sep 30, 2024 | 1.96 Mn |
| Jun 30, 2024 | 829,000.00 |
| Mar 31, 2024 | 978,000.00 |
| Dec 31, 2023 | 154,000.00 |